Literature DB >> 8306452

Determination of changes in serum lathosterol during treatment with simvastatin to evaluate the role of lathosterol as a parameter for whole body cholesterol synthesis.

I De Cuyper1, B G Wolthers, J J van Doormaal, P N Wijnandts.   

Abstract

Serum levels of cholesterol and the cholesterol precursor lathosterol were determined in five healthy volunteers who took 20 mg simvastatin daily during 1 week. During this period and for the following 5 days blood samples were collected. Five days after ingestion of simvastatin, serum lathosterol had already reached a steady-state level and its concentration decreased by 55-73%. In contrast, the cholesterol concentration decreased only by 17-29% and did not reach a steady-state level even after 7 days of treatment. After withdrawal of simvastatin, serum lathosterol quickly rose to pretreatment values. From the data a mean half-life of lathosterol could be calculated of 23.5 +/- 6.6 h during treatment with simvastatin and of 28.7 +/- 15.1 h after its withdrawal, taking, respectively, the decrease and increase of serum lathosterol into account. From these data it can be concluded that serum lathosterol is also a good parameter for determining whole body cholesterol synthesis during non-steady-state conditions, although plasma mevalonic acid, another (early) cholesterol precursor, is preferred owning to its much shorter reported half-life.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8306452     DOI: 10.1016/0009-8981(93)90203-g

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

1.  Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.

Authors:  Nuntakorn Thongtang; Jianxin Lin; Ernst J Schaefer; Robert S Lowe; Joanne E Tomassini; Arvind K Shah; Andrew M Tershakovec
Journal:  Atherosclerosis       Date:  2012-09-13       Impact factor: 5.162

2.  Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.

Authors:  Marianne K DeGorter; Rommel G Tirona; Ute I Schwarz; Yun-Hee Choi; George K Dresser; Neville Suskin; Kathryn Myers; GuangYong Zou; Otito Iwuchukwu; Wei-Qi Wei; Russell A Wilke; Robert A Hegele; Richard B Kim
Journal:  Circ Cardiovasc Genet       Date:  2013-07-22

3.  Deficiency of ASGR1 in pigs recapitulates reduced risk factor for cardiovascular disease in humans.

Authors:  Baocai Xie; Xiaochen Shi; Yan Li; Bo Xia; Jia Zhou; Minjie Du; Xiangyang Xing; Liang Bai; Enqi Liu; Fernando Alvarez; Long Jin; Shaoping Deng; Grant A Mitchell; Dengke Pan; Mingzhou Li; Jiangwei Wu
Journal:  PLoS Genet       Date:  2021-11-11       Impact factor: 5.917

4.  De novo lipogenesis and cholesterol synthesis in humans with long-standing type 1 diabetes are comparable to non-diabetic individuals.

Authors:  Jennifer E Lambert; Edmond A Ryan; Alan B R Thomson; Michael T Clandinin
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.